Azide–Alkyne Cycloaddition En Route to 1H-1,2,3-Triazole-Tethered

This is an open access article published under an ACS AuthorChoice License, which permits copying and redistribution of the article or any adaptations for non-commercial purposes.

Article Cite This: ACS Omega 2018, 3, 1263−1268

Azide−Alkyne Cycloaddition En Route to 1H‑1,2,3-Triazole-Tethered Isatin−Ferrocene, Ferrocenylmethoxy−Isatin, and Isatin− Ferrocenylchalcone Conjugates: Synthesis and Antiproliferative Evaluation Amandeep Singh,† Sourav Taru Saha,‡ Shanen Perumal,‡ Mandeep Kaur,*,‡ and Vipan Kumar*,† †

Department of Chemistry, Guru Nanak Dev University, Amritsar 143005, India School of Molecular and Cell Biology, University of the Witwatersrand, Private Bag 3, Wits, 2050 Johannesburg, South Africa

‡

S Supporting Information *

ABSTRACT: Diverse series of isatin−ferrocene conjugates were synthesized via Cu-promoted azide−alkyne cycloaddition reaction with an aim of probing their antiproliferative structure−activity relationship against MCF-7 (estrogen receptor positive) and MDA-MB-231 (triple negative) cell lines. Among the synthesized conjugates, isatin−ferrocenes proved to be more potent against MCF-7, whereas ferrocenylmethoxy−isatins exhibited activity against MDA-MB-231 cell lines. However, the introduction of chalcone moiety among these hybrids resulted in the complete loss of activity against the tested cell lines, as evident by isatin−ferrocenylchalcones. The conjugates 5a and 9c proved to be the most potent among the series against MCF-7 and MDA-MB-213 cell lines, exhibiting IC50 values of 31.62 and 20.26 μM, respectively.

■

INTRODUCTION Cancer, characterized by abnormal growth of cells, is the second most fatal disease in the world. The use of tobacco, over body weight, gene mutation, and hormone and immune conditions are few driving forces responsible for the emergence of this deadly disease.1 Breast cancer is considered one of the most common cancers with a high rate of mortality.2 Formation of lumps in the breast tissue is the prevalent symptom of breast cancer, while less common symptoms may include persistent changes in the breast such as thickness, swelling, distortion, and spontaneous nipple discharge.1 In United States, 30% of women are expected to develop breast cancer over their lifetime, with an expected 40 610 breast cancer-related deaths in 2017.3 The efficacy of current chemotherapeutics against breast cancer is low, and significant improvements are achieved only in 30−40% of the patients.4 Worldwide, medicinal chemists are striving to discover novel, effectual, and less toxic antibreast cancer agents which can expand the success spectrum among cancer cases. Isatin (1H-indole-2,3-dione) is a privileged scaffold present endogenously in both human and other mammalian tissues. The molecular architecture of isatin is indeed an ideal platform for carrying out structural modification and derivatization to probe its further biological potential.5 Isatin derivatives have been reported to exhibit a range of biological properties such as anticancer,6 antidepressant,7 anticonvulsant,8 antifungal,9 antiHIV,10 and antiinflammatory11 activities. The Food and Drug Administration approval of SU11248 (SUTENT), a 5-fluoro-3© 2018 American Chemical Society

substituted isatin derivative for the treatment of advanced renal carcinoma and gastrointestinal stromal tumors, has established isatin as a potentially useful lead for anticancer drug development.12 C-5- and C-6-substituted isatin analogues were selective monoamine oxidase B inhibitors, with 5-(4phenylbutyl)isatin being 18 500-fold more potent than the parent molecule.13 A number of reports have appeared lately on the anticancer activities of isatin conjugates, which proved them to be more efficient than cis-platin.14 Tyrosine kinase inhibition, inhibition of cyclin-dependent kinases, and/or caspase inhibition are some pathways through which isatin has been reported to exhibit its anticancer potential.15 The application of bioorganometallic chemistry in medicine, especially via the inclusion of the ferrocene nucleus among organic frameworks, is a rapidly developing area of research.15b Numerous studies have suggested that the replacement of an aryl ring with a ferrocenyl moiety has improved the biological activities of the heterocyclic scaffolds or has fashioned new medicinal properties.16 The most emblematic example of such a strategy could be of ferrocifen, obtained via replacement of one of the phenyl rings of tamoxifen with ferrocene, resulting in the development of the earliest organometallic selective estrogen receptor modulators. Ferrocifen displayed an uncommon feature of being antiproliferative against both hormoneReceived: November 9, 2017 Accepted: January 10, 2018 Published: January 30, 2018 1263

DOI: 10.1021/acsomega.7b01755 ACS Omega 2018, 3, 1263−1268

Article

ACS Omega

Figure 1. Designed 1H-1,2,3-triazole tethered isatin−ferrocene, ferrocenylmethoxy−isatin, and isatin−ferrocenyl−chalcone conjugates.

Scheme 1. Synthesis of 1H-1,2,3-Triazole-Linked Isatin−Ferrocene Conjugates 5a−h

■

RESULTS AND DISCUSSION Synthetic methodology for obtaining the desired isatin− ferrocene conjugate 5 involved an initial base-promoted Nalkylation of 5-substituted isatin 1 with methyl iodide or benzyl bromide in dry dimethyl formamide to yield N-alkylated isatin 2 which was subsequently reacted with trimethylsilyl iodide to afford spiroindoline-oxirane-2-ones 3. Epoxide ring opening of 3 with sodium azide in an ethanol/water (90:10) mixture afforded 3-(azidomethyl)-3-hydroxy-indolin-2-one 4. Cu-promoted azide−alkyne cycloaddition of 4 with ethynyl ferrocene resulted in the formation of a crude product which was purified by column chromatography using (10:90) a methanol/ chloroform mixture as the eluent to afford the desired 1H1,2,3-triazole-tethered isatin−ferrocene conjugate 5 in good yields (Scheme 1). Another precursor, viz., O-propargylated ferrocene methanol 8, required for ferrocenylmethoxy−isatin conjugates, was synthesized via NaBH4-promoted reduction of ferrocene carboxaldehyde 6 in dry tetrahydrofuran to afford ferrocene methanol 7 with subsequent O-propargylation using sodium hydride. Cu-promoted azide−alkyne cycloaddition reaction of 4 with O-propargylated-ferrocene methanol 8 led to the isolation

dependent (MCF-7) and hormone-independent (MDA-MB231) breast cancer cell lines. Such a dual mode of action underlines the importance of replacing the aryl ring with ferrocene because the purely organic form exhibited antiestrogenic activity only against MCF-7 cell lines.17 With an aim of discovering varied biologically relevant molecular conjugates,18 the present manuscript is one of our endeavors toward targeting breast cancer which includes the synthesis of a series of 1H-1,2,3-triazole-linked isatin− ferrocene, ferrocenylmethoxy−isatin, and isatin−ferrocenyl− chalcone conjugates, as depicted in Figure 1. These molecules were evaluated for their antiproliferative activities against estrogen receptor positive (ER+) MCF-7 cells and triple negative (ER−) MDA-MB-231 cells. 1H-1,2,3-Triazole core has drawn considerable attention in the field of medicinal chemistry mainly because of its capability of forming H-bonds, which eventually improves its solubility and interaction with biomolecular targets. The stability toward metabolic degradation as well as varied biological activities make 1H-1,2,3-triazole a privileged scaffold which can be used as a linker in the molecular-hybridization approach.19 1264

DOI: 10.1021/acsomega.7b01755 ACS Omega 2018, 3, 1263−1268

Article

ACS Omega Scheme 2. Synthesis of 1H-1,2,3-Triazole-Linked Ferrocenylmethoxy−Isatin Conjugates 9a−h

Scheme 3. Synthesis of 1H-1,2,3-Triazole-Linked Isatin−Ferrocenylchalcone Conjugates 13a−h

Table 1. IC50 Values of the Test Compounds in MCF-7 and MDA-MB-231 Cellsa

a

compounds

MCF-7 (μM)

MDA-MB-231 (μM)

log p

compounds

MCF-7 (μM)

MDA-MB-231 (μM)

log p

5a 5b 5c 5d 5e 5f 5g 5h 9a 9b 9c 9d tamoxifen plumbagin

31.62 61.86 68.91 79.23 53.48 57.10 75.88 34.99 70.30 70.31 67.34 ND 50 3.2

97.11 71.19 70.26 80.12 64.67 47.51 69.60 33.73 63.34 45.67 20.26 ND 75 4.4

−2.60 −2.09 −1.81 −2.14 −0.83 −0.31 −0.04 −0.36 −3.02 −2.50 −2.23 ND

9e 9f 9g 9h 13a 13b 13c 13d 13e 13f 13g 13h

ND 78.30 ND 67.02 68.73 67.84 69.02 66.69 55.70 69.02 70.71 >100

ND 38.29 ND 55.27 76.88 >100 96.93 89.39 >100 70.71 72.10 >100

−1.24 −0.72 ND −0.77 −1.38 −0.87 −0.59 −0.92 0.39 0.91 1.18 0.86

ND = not determined.

of a crude solid, which was purified via column chromatography using a CHCl3/methanol (95:5) mixture as the eluent, to yield the desired conjugate 9 in good yields (Scheme 2). The structure to the synthesized conjugate was assigned on the basis of spectral studies and analytical evidence. The compound, for

example 9a, exhibited a molecular ion peak at 351.1457 in its high resolution mass spectrum. Its proton nuclear magnetic resonance (1H NMR) spectrum showed the presence of a singlet at δ 4.18, corresponding to 5H (cyclopentadiene ring of ferrocene), along with singlets at δ 4.33 (2H) and 4.61 (2H) 1265

DOI: 10.1021/acsomega.7b01755 ACS Omega 2018, 3, 1263−1268

Article

ACS Omega

Cu-promoted azide−alkyne cycloaddition reaction along with the evaluation of their antiproliferative activities against MCF-7 (ER+) and MDA-MB-231 (ER−) cell lines. The activity data revealed the ferrocenylmethoxy−isatins to be more selective against ER− cell lines, and thus, it can open up avenues for further investigation into this type of molecular framework for developing targeted therapies against ER− breast cancer. Furthermore, isatin−ferrocene conjugates exhibited selectivity against the ER+ cell line, and further modifications may prove useful for treating about 70% of all breast cancer patients. It would also be useful to test these compounds against tamoxifen-resistant cell lines in future to examine if these compounds have the ability to inhibit the growth of tamoxifenresistant breast cancer cells.

because of the ferrocene ring protons. The appearance of a pair of singlets at δ 4.18 (2H) and 4.26 (2H), corresponding to O− CH2, along with a characteristic singlet at δ 7.74 (1H) because of the triazole ring proton confirmed the assigned structure. The appearance of absorption peaks at δ 68.6, 68.7, 69.6, and 75.1 due to ferrocene ring carbons along with the presence of absorption peak δ 175.3 due to the isatin ring carbonyl in the 13 C NMR spectrum further corroborated the assigned structure. A precursor, viz., O-propargylated ferrocenyl chalcone 12, was prepared via an initial propargylation of 4-hydroxyacetophenone 10 to yield 11, which was subjected to aldol condensation with ferrocene−carboxaldehyde 8. Cu-promoted azide−alkyne cycloaddition reaction between 3-(azidomethyl)3-hydroxy-indolin-2-one 4 and 12 afforded the desired 1H1,2,3-triazole-tethered isatin−ferrocenylchalcone conjugate 13, as depicted in Scheme 3, the structure to which were again assigned on the basis of spectral data and analytical evidences. The synthesized 1H-1,2,3-triazole-tethered isatin−ferrocene, ferrocenylmethoxy−isatin, and isatin−ferrocenylchalcone conjugates were then evaluated for their antiproliferative activities against MCF-7 (ER+) and MDA-MB-231 (ER−) human breast cancer cell lines using 3-(4,5-dimethylthiazol-z-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The percentages of growth inhibition of MCF-7 and MDA-MB-231 cells were recorded at varying concentrations of the synthesized conjugates, and the results are depicted in Figures S13−S19 (Supporting Information), using plumbagin as the positive control. IC50 values, which is the concentration required to inhibit the growth of 50% of the cells by the test compounds, is summarized in Table 1. As evident, the compounds proved to be more active or cytotoxic to MCF-7 cells compared to MDAMB-231 cells. A closer inspection of Table 1 revealed an interesting structure−activity relationship, with antiproliferative activities being dependent upon the basic framework of the synthesized conjugates. 1H-1,2,3-Triazole-tethered isatin− ferrocene conjugates, 5a, 5e, 5f, and 5h, proved to be potent against MCF-7 cell lines compared to MDA-MB-231 cell lines, exhibiting IC50 values of 31.62, 53.48, 57.10, and 34.99 μM, respectively. In particular, the conjugate 5a exhibited selectivity against the MCF-7 over the MDA-MB-231 cell line, where a concentration of 97.11 μM is needed to inhibit the growth. 1H1,2,3-Triazole-tethered ferrocenylmethoxy−isatin conjugates, viz., 9b, 9c, and 9f, on the other hand, showed selectivity against the MDA-MB-231 over MCF-7 cell lines, as evident by their low IC50 values. 9b, 9c, and 9f exhibited IC50 values of 45.67, 20.26, and 38.29 μM, respectively, against the ER− cell line, whereas IC50 values of 70.31, 67.34, and 78.30 μM were observed against the ER+ cell line, with an exception being 5h, which proved to be effective against both ER+ as well as ER− cell lines, exhibiting IC50s of 34.99 and 33.73 μM, respectively. The introduction of the chalcone moiety among isatin− ferrocene conjugates, viz., 13a−h, reduced the antiproliferative activities, with conjugate 13h proving to be ineffective against both the cell lines. The loss of activity with the inclusion of the chalcone moiety among the synthesized hybrids could be attributed to its reported induction of cytoprotective enzymes.20 The log p values for all the tested conjugates were also calculated (Table S1) and were lower than 5.0, indicative of the fact that the compounds are not lipophilic.

■

EXPERIMENTAL SECTION General Information. Melting points were determined by an open capillary using a Veego precision digital melting point apparatus (MP-D) and are uncorrected. 1H NMR spectra were recorded in CDCl3 with a Bruker AVANCE II (500 MHz) spectrometer using tetramethylsilane (TMS) as the internal standard. Chemical shift values are expressed as parts per million downfield from TMS, and the J values are in hertz. Splitting patterns are indicated as s: singlet, d: doublet, t: triplet, m: multiplet, dd: double doublet, ddd: doublet of a doublet of a doublet, and br: broad peak. 13C NMR spectra were recorded in CDCl3 with a Bruker AVANCE II (125 MHz) spectrometer using TMS as the internal standard. Mass spectra were recorded on a Bruker high resolution mass spectrometer (micrOTOF-QII). Elemental analyses were performed on a Heraeus CHN-O-Rapid elemental analyzer.19e Column chromatography was performed on a silica gel (60−120 mesh) using an ethyl chloroform/hexane mixture as the eluent. Procedure for the Synthesis of Isatin−Ferrocene Conjugates (5a−h). Copper sulfate (0.05 mmol) and sodium ascorbate (0.13 mmol) were added to a well-stirred solution of ethynyl ferrocene (1 mmol) and N-alkylazido-isatin 4 (1 mmol) in an ethanol/water (90:10) mixture.19e The reaction mixture was stirred at room temperature for 10−12 h, and the progress was monitored via thin-layer chromatography (TLC). On completion, water (20 mL) was added, and the extractions were carried out with dichloromethane (2 × 30 mL). The combined organic layers were dried over anhydrous sodium sulfate and concentrated under vacuum to yield a crude product 5, which was purified via column chromatography using a 10:90 (methanol/chloroform) mixture. Procedure for the Synthesis of Ferrocenylmethoxy− Isatin Conjugates (9a−h). Copper sulfate (0.05 mmol) and sodium ascorbate (0.13 mmol) were added to a stirred solution of O-propargylated ferrocenyl-methanol 8 (1 mmol) and Nalkylazido-isatin 4 (1 mmol) in an ethanol/water (95:5) mixture. The reaction mixture was allowed to stir for 6−8 h at room temperature, and the progress was monitored via TLC. Water (20 mL) was added, and the reaction mixture was extracted with dichloromethane (2 × 30 mL). The combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure to yield a crude product 9, which was purified via column chromatography using a 5:95 (methanol/chloroform) mixture. Procedure for the Synthesis of Isatin−Ferreocenylchalcone Conjugates (13a−h). To a stirred solution of ferrocenyl chalcone 12 (1 mmol) and N-alkylated-azido-isatin 4 (1 mmol) in an ethanol/water mixture, were added copper

■

CONCLUSIONS A series of isatin−ferrocene, ferrocenylmethoxy−isatin, and isatin−ferrocenylchalcone conjugates were synthesized via a 1266

DOI: 10.1021/acsomega.7b01755 ACS Omega 2018, 3, 1263−1268

ACS Omega sulfate (0.05 mmol) and sodium ascorbate (0.13 mmol). The reaction mixture was allowed to stir at room temperature for 8−10 h. After completion, as evident by TLC, water (20 mL) was added, and the extraction was carried out with dichloromethane (2 × 30 mL). The combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure to yield a crude product 13, which was purified via column chromatography using a 5:95 (methanol/chloroform) mixture. Materials and Methods. The cytotoxicity of conjugates, viz., 5a−h, 9a−h, and 13a−h, was tested on two different breast cancer cell lines, namely, ER+ MCF-7 cells and triple negative MDA-MB-231 (ER−) using MTT assay.21 Cell Culturing. MCF-7 cells were cultured in complete Dulbecco’s media Eagle’s medium (DMEM) with 5% fetal bovine serum (FBS) and 1% penicillin−streptomycin, and MDA-MB-231 cells were cultured in 3:1 DMEM and Ham’s F12 with 10% FBS and 1% penicillin−streptomycin; both cell lines were incubated at 37 °C and 5% carbon dioxide. Methods. Cells were seeded in 96-well plates at a density of 5000 cells per well in triplicate in media. After 24 h, the test compounds [dissolved in dimethyl sulfoxide with concentration 0.5 were included in the statistical analysis.23

■

■

ACKNOWLEDGMENTS

■

REFERENCES

Financial assistance from the University Grants Commission (UGC), New Delhi, India, under UGC-JRF Fellowship (A.S.) ref no. 23/12/2012(ii)EU-V is gratefully acknowledged. NRF Rating incentive funding to M.K. is also acknowledged. V.K. also acknowledges the Council of Scientific and Industrial Research (CSIR, New Delhi) for financial assistance (grant no. 02(0293)/17/EMR-I).

(1) Cancer Fact and Figure American Cancer Society. https://www. cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/ cancer-facts-figures-2017.html (page visited on 17-11-2017), 2017, pp 1−71. (2) DeSantis, C. E.; Fedewa, S. A.; Sauer, A. G.; Kramer, J. L.; Smith, R. A.; Jemal, A. Breast cancer statistics, 2015: Convergence of incidence rates between black and white women. Ca-Cancer J. Clin. 2016, 66, 31−42. (3) Siegel, R. L.; Miller, K. D.; Jemal, A. Cancer Statistics, 2017. CaCancer J. Clin. 2017, 67, 7−30. (4) Karthikeyan, C.; Solomon, V. R.; Lee, H.; Trivedi, P. Design, synthesis and biological evaluation of some isatin-linked chalcones as novel anti-breast cancer agents: A molecular hybridization approach. Biomed. Prev. Nutr. 2013, 3, 325−330. (5) Teng, Y.-O.; Zhao, H.-Y.; Wang, J.; Liu, H.; Gao, M.-L.; Zhou, Y.; Han, K.-L.; Fan, Z.-C.; Zhang, Y.-M.; Sun, H.; Yu, P. Synthesis and anti-cancer activity evaluation of 5-(2-carboxyethenyl)-isatin derivatives. Eur. J. Med. Chem. 2016, 112, 145−156. (6) Ibrahim, H. S.; Abou-Seri, S. M.; Tanc, M.; Elaasser, M. M.; Abdel-Aziz, H. A.; Supuran, C. T. Isatin-pyrazole benzenesulfonamide hybrids potently inhibit tumor-associated carbonic anhydrase isoforms IX and XII. Eur. J. Med. Chem. 2015, 103, 583−593. (7) Rohini, R.; Reddy, P. M.; Shanker, K.; Kanthaiah, K.; Ravinder, V.; Hu, A. Synthesis of mono, bis-2-(2-arylideneaminophenyl) indole azomethines as potential antimicrobial agents. Arch. Pharmacal Res. 2011, 34, 1077−1084. (8) Pandeya, S. N.; Smitha, S.; Jyoti, M.; Sridhar, S. K. Biological activities of isatin and its derivatives. Acta Pharm. 2005, 55, 27−46. (9) Meena, K.; Kumari, S.; Khurana, J. M.; Malik, A.; Sharma, C.; Panwar, H. One pot three component synthesis of spiro [indolo-3,10′indeno[1,2-b] quinolin]-2,4,11′-triones as a new class of antifungal and antimicrobial agents. Chin. Chem. Lett. 2017, 28, 136−142. (10) Devale, T. L.; Parikh, J.; Miniyar, P.; Sharma, P.; Shrivastava, B.; Murumkar, P. Dihydropyrimidinone-isatin hybrids as novel nonnucleoside HIV-1 reverse transcriptase inhibitors. Bioorg. Chem. 2017, 70, 256−266. (11) Akhaja, T. N.; Raval, J. P. Design, synthesis and in vitro evaluation of tetrahydropyrimidine−isatin hybrids as potential antitubercular and antimalarial agents. Chin. Chem. Lett. 2012, 23, 785−788. (12) Prenen, H.; Cools, J.; Mentens, N.; Folens, C.; Sciot, R.; Schöffski, P. Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate. Clin. Cancer Res. 2006, 12, 2622−2627. (13) Manley-King, C. I.; Bergh, J. J.; Petzer, J. P. Inhibition of monoamine oxidase by selected C5- and C6-substituted isatin analogues. Bioorg. Med. Chem. 2011, 19, 261−274. (14) Karthikeyan, C.; Solomon, V. R.; Lee, H.; Trivedi, P. Design, synthesis and biological evaluation of some isatin-linked chalcones as novel anti-breast cancer agents: A molecular hybridization approach. Biomed. Prev. Nutr. 2013, 3, 325−330. (15) (a) Nam, S.; Buettner, R.; Turkson, J.; Kim, D.; Cheng, J. Q.; Muehlbeyer, S.; Hippe, F.; Vatter, S.; Merz, K.-H.; Eisenbrand, G.; Jove, R. Indirubin derivatives inhibit Stat3 signaling and induce apoptosis in human cancer cells. Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 5998−6003. (b) Chu, W.; Rothfuss, J.; Zhou, D.; Mach, R. H. Synthesis and evaluation of isatin analogs as caspase-3 inhibitors:

ASSOCIATED CONTENT

S Supporting Information *

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acsomega.7b01755. Synthesis and characterization data of compounds 5a−h, 9a−h, and 13a−h, scanned (1H and 13C) NMR spectra for the compounds, viz., 5f, 9a, 9f, 13a, 13c, and 13d, and percentage inhibition graphs (PDF)

■

Article

AUTHOR INFORMATION

Corresponding Authors

*E-mail: [email protected] (M.K.). *E-mail: [email protected] (V.K.). ORCID

Vipan Kumar: 0000-0002-6164-7161 Notes

The authors declare no competing financial interest. 1267

DOI: 10.1021/acsomega.7b01755 ACS Omega 2018, 3, 1263−1268

Article

ACS Omega Introduction of a hydrophilic group increases potency in a whole cell assay. Bioorg. Med. Chem. Lett. 2011, 21, 2192−2197. (16) (a) Top, S.; Vessières, A.; Leclercq, G.; Quivy, J.; Tang, J.; Vaissermann, J.; Huché, M.; Jaouen, G. Synthesis, Biochemical Properties and Molecular Modelling Studies of Organometallic Specific Estrogen Receptor Modulators (SERMs), the Ferrocifens and Hydroxyferrocifens: Evidence for an Antiproliferative Effect of Hydroxyferrocifens on both Hormone-Dependent and HormoneIndependent Breast Cancer Cell Lines. Chem.Eur. J. 2003, 9, 5223− 5236. (b) Payen, O.; Top, S.; Vessières, A.; Brulé, E.; Plamont, M.-A.; McGlinchey, M. J.; Müller-Bunz, H.; Jaouen, G. Synthesis and Structure−Activity Relationships of the First Ferrocenyl-Aryl-Hydantoin Derivatives of the Nonsteroidal Antiandrogen Nilutamide. J. Med. Chem. 2008, 51, 1791−1799. (c) Gasser, G.; Metzler-Nolte, N. The potential of organometallic complexes in medicinal chemistry. Curr. Opin. Chem. Biol. 2012, 16, 84−91. (d) Quirante, J.; Dubar, F.; Gonzalez, A.; Lopez, C.; Cascante, M.; Cortes, R.; Forfar, I.; Pradines, B.; Biot, C. Ferrocene-indole hybrids for cancer and malaria therapy. J. Organomet. Chem. 2011, 696, 1011−1017. (e) Radulović, N. S.; Zlatković, D. B.; Mitić, K. V.; Randjelović, P. J.; Stojanović, N. M. Synthesis, spectral characterization, cytotoxicity and enzyme-inhibiting activity of new ferrocene−indole hybrids. Polyhedron 2014, 80, 134− 141. (17) (a) Bruijnincx, P. C. A.; Sadler, P. J. New trends for metal complexes with anticancer activity. Curr. Opin. Chem. Biol. 2008, 12, 197−206. (b) Yu, H.; Shao, L.; Fang, J. Synthesis and biological activity research of novel ferrocenyl-containing thiazole imine derivatives. J. Organomet. Chem. 2007, 692, 991−996. (18) Jaouen, G.; Vessières, A.; Top, S. Ferrocifen type anti cancer drugs. Chem. Soc. Rev. 2015, 44, 8802−8817. (19) (a) Kumar, K.; Singh, P.; Kremer, L.; Guérardel, Y.; Biot, C.; Kumar, V. Synthesis and in vitro anti-tubercular evaluation of 1,2,3triazole tethered β-lactam−ferrocene and β-lactam−ferrocenylchalcone chimeric scaffolds. Dalton Trans. 2012, 41, 5778. (b) Kumar, K.; Carrère-Kremer, S.; Kremer, L.; Guérardel, Y.; Biot, C.; Kumar, V. Azide−alkyne cycloaddition en route towards 1H-1,2,3-triazoletethered β-lactam−ferrocene and β-lactam−ferrocenylchalcone conjugates: synthesis and in vitro anti-tubercular evaluation. Dalton Trans. 2013, 42, 1492. (c) Kumar, K.; Carrère-Kremer, S.; Kremer, L.; Guérardel, Y.; Biot, C.; Kumar, V. 1H-1,2,3-Triazole-Tethered Isatin− Ferrocene and Isatin−Ferrocenylchalcone Conjugates: Synthesis and in Vitro Antitubercular Evaluation. Organometallics 2013, 32, 5713. (d) Kumar, K.; Biot, C.; Carrère-Kremer, S.; Kremer, L.; Guérardel, Y.; Roussel, P.; Kumar, V. Base-Promoted Expedient Access to Spiroisatins: Synthesis and Antitubercular Evaluation of 1H-1,2,3Triazole-Tethered Spiroisatin−Ferrocene and Isatin−Ferrocene Conjugates. Organometallics 2013, 32, 7386. (e) Singh, A.; Gut, J.; Rosenthal, J. P.; Kumar, V. 4-Aminoquinoline-ferrocenyl-chalcone conjugates: Synthesis and anti-plasmodial evaluation. Eur. J. Med. Chem. 2017, 125, 269−277. (20) Kolb, H. C.; Sharpless, K. B. The growing impact of click chemistry on drug discovery. Drug Discovery Today 2003, 8, 1128. (21) (a) Peng, S.; Hou, Y.; Yao, J.; Fang, J. Activation of Nrf2-driven antioxidant enzymes by cardamonin confers neuroprotection of PC12 cells against oxidative damage. Food Funct. 2017, 8, 997−1007. (b) Peng, S.; Yao, J.; Liu, Y.; Duan, D.; Zhang, X.; Fang, J. Activation of Nrf2 target enzymes conferring protection against oxidative stress in PC12 cells by ginger principal constituent 6-shogaol. Food Funct. 2015, 6, 2813−2823. (c) Peng, S.; Zhang, B.; Meng, X.; Yao, J.; Fang, J. Synthesis of Piperlongumine Analogues and Discovery of Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2) Activators as Potential Neuroprotective Agents. J. Med. Chem. 2015, 58, 5242−5255. (d) Yao, J.; Zhang, B.; Ge, C.; Peng, S.; Fang, J. Xanthohumol, a Polyphenol Chalcone Present in Hops, Activating Nrf2 Enzymes To Confer Protection against Oxidative Damage in PC12 Cells. J. Agric. Food Chem. 2015, 63, 1521−1531. (e) Yao, J.; Ge, C.; Duan, D.; Zhang, B.; Cui, X.; Peng, S.; Liu, Y.; Fang, J. Activation of the Phase II Enzymes for Neuroprotection by Ginger Active Constituent 6-Dehydrogingerdione in PC12 Cells. J. Agric. Food Chem. 2014, 62, 5507−5518.

(22) Sagar, S.; Esau, L.; Moosa, B.; Khashab, N.; Bajic, V.; Kaur, M. Cytotoxicity and Apoptosis Induced by a Plumbagin Derivative in Estrogen Positive MCF-7 Breast Cancer Cells. Anti Canc. Agents Med. Chem. 2014, 14, 170−180. (23) Zhang, J.-H.; Chung, T. D. Y.; Oldenburg, K. R. A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J. Biomol. Screening 1999, 4, 67−73.

1268

DOI: 10.1021/acsomega.7b01755 ACS Omega 2018, 3, 1263−1268